摘要
目的评价曲美他嗪治疗不稳定型心绞痛的疗效。方法我院47例符合标准的不稳定型心绞痛患者随机分为对照组(24例)和治疗组(23例)。对照组患者给予基础治疗(硝酸酯类,β-受体阻滞剂,抗凝剂及阿司匹林等),治疗组在此基础上加用曲美他嗪,疗程均为4周。治疗前、后检查心电图,记录心绞痛发作次数及每次心绞痛发作的平均时间以及心率、血压的变化。结果两组患者临床疗效间差异有显著性意义(P<0.01),治疗组患者治疗前、后心绞痛发作次数、持续时间及对照组患者治疗前、后心绞痛发作次数、持续时间差异均有显著性意义(P<0.05)。两组患者治疗后心绞痛发作次数、持续时间差异亦均有显著性意义(P<0.05)。曲美他嗪对心率、血压无影响。结论曲美他嗪治疗不稳定型心绞痛疗效确切,值得临床推广使用。
Objective To investigate the therapeutic results of trimetazidine for unstable angina pectoris （UAP）. Methods 47 patients with UAP were randomly assigned to receive trimetazidine in addition to conventional therapy for 4 weeks （ n = 23 ） or conventional therapy consisting of nitrate, β -blocker and aspirin （n =24, control group）. Clinical effectiveness and changes in eleetroeardiogram, heart rate and blood pressure were evaluated. Results The clinical effectiveness was significantly better in trimetazidine group patients than in control group patients（ P 〈 0. 01 ）. The differences in frequency and duration of angina attack were statistically different before and after treatment in both groups of patients （ P 〈0.05 ）. The differenees in frequency and duration of angina attack were statistically different after treatment between two groups （ P 〈0.05 ）. Trimetazidine had no significant effect on heart rate and blood pressure. Conclusion Trimetazidine is useful for UAP, and deserves recommendation.
出处
《临床和实验医学杂志》
2007年第9期22-22,24,共2页
Journal of Clinical and Experimental Medicine
